Alpha 2.0
Login Register
» Authors » Jason Flamm

Jason Flamm

Explore the profile of Jason Flamm including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 18
Citations 1073
Followers 0
Related Specialties
Infectious Diseases
Pharmacology
Biology
Top 10 Co-Authors
Thomas Prindiville
Satya Dandekar
Moraima Guadalupe
Elizabeth Reay
Sumathi Sankaran
C Bradley Hare
Michael D George
Sally Slome
Derek D Satre
Michael J Silverberg
Published In
J Virol
HIV Clin Trials
AIDS Patient Care STDS
J Int AIDS Soc
J Affect Disord
Affiliations
Soon will be listed here.
Recent Articles
1.
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial
Wohl D, Spinner C, Flamm J, Hare C, Doblecki-Lewis S, Ruane P, et al.
Lancet HIV . 2024 Jul; 11(8):e508-e521. PMID: 39008999
Background: Data characterising the long-term use and safety of emtricitabine plus tenofovir disoproxil fumarate as daily oral pre-exposure prophylaxis (PrEP) are scarce and there are uncertainties regarding the value of...
2.
Factors associated with suicidal ideation among people with HIV engaged in care
Satre D, Sarovar V, Levine T, Leibowitz A, Lea A, Ridout K, et al.
J Affect Disord . 2024 May; 358:369-376. PMID: 38723683
Background: People with HIV (PWH) are at elevated risk for suicidal ideation (SI), yet few studies have examined how substance use, clinical and sociodemographic factors are associated with SI among...
3.
Mental health and substance use screening in HIV primary care before and during the early COVID-19 pandemic
Lea A, Levine T, Davy-Mendez T, Leibowitz A, Altschuler A, Flamm J, et al.
BMC Health Serv Res . 2023 May; 23(1):494. PMID: 37194051
Background: Mental health and substance use disorders disproportionately affect people with HIV (PWH), and may have been exacerbated during COVID-19. The Promoting Access to Care Engagement (PACE) trial was designed...
4.
Implementing electronic substance use disorder and depression and anxiety screening and behavioral interventions in primary care clinics serving people with HIV: Protocol for the Promoting Access to Care Engagement (PACE) trial
Satre D, Anderson A, Leibowitz A, Levine-Hall T, Slome S, Flamm J, et al.
Contemp Clin Trials . 2019 Aug; 84:105833. PMID: 31446142
Background: Substance use disorders (SUDs) and psychiatric disorders are common among people with HIV (PWH) and lead to poor outcomes. Yet these conditions often go unrecognized and untreated in primary...
5.
Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI
Pozniak A, Flamm J, Antinori A, Bloch M, Ward D, Berenguer J, et al.
HIV Clin Trials . 2017 Jul; 18(4):141-148. PMID: 28689453
Background: HIV-1-infected, virologically suppressed adults wanting to simplify or change their non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens may benefit from switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and...
6.
Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis
Stellbrink H, Antinori A, Pozniak A, Flamm J, Bredeek F, Patel K, et al.
J Int AIDS Soc . 2014 Nov; 17(4 Suppl 3):19793. PMID: 25397537
Introduction: Switch to Stribild (STB) was non-inferior to continuation of a non-nucleoside reverse transcriptase inhibitor (NNRTI) with emtricitabine and tenofovir DF (FTC/TDF) at week 48 in virologically suppressed HIV adults...
7.
Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants
Palella Jr F, Fisher M, Tebas P, Gazzard B, Ruane P, van Lunzen J, et al.
AIDS . 2014 Mar; 28(3):335-44. PMID: 24670520
Objective: To evaluate the efficacy and safety of antiretroviral simplification from a ritonavir-boosted protease inhibitor-based regimen [protease inhibitor+RTV+two nucleos(t)ide reverse transcriptase inhibitors (NRTIs); ≥6 months of exposure prior to study...
8.
Sex differences matter in the gut: effect on mucosal immune activation and inflammation
Sankaran-Walters S, Macal M, Grishina I, Nagy L, Goulart L, Coolidge K, et al.
Biol Sex Differ . 2013 May; 4(1):10. PMID: 23651648
Background: Women and men have diverse responses to many infectious diseases. These differences are amplified following menopause. However, despite extensive information regarding the effects of sex hormones on immune cells,...
9.
Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96
Fourie J, Flamm J, Rodriguez-French A, Kilby D, Domingo P, Lazzarin A, et al.
HIV Clin Trials . 2011 Dec; 12(6):313-22. PMID: 22189150
Objectives: ARTEMIS demonstrated significantly greater efficacy of once-daily darunavir/ritonavir (DRV/r) 800/100 mg versus lopinavir/ritonavir 800/200 mg (total daily dose) in treatment-naïve, HIV-1-infected patients at week 96. The influence of baseline...
10.
The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy
Lerner P, Guadalupe M, Donovan R, Hung J, Flamm J, Prindiville T, et al.
J Virol . 2011 Feb; 85(10):4772-82. PMID: 21345945
Interruption of suppressive highly active antiretroviral therapy (HAART) in HIV-infected patients leads to increased HIV replication and viral rebound in peripheral blood. Effects of therapy interruption on gut-associated lymphoid tissue...